Shalini Subramaniam (@shalsubra) 's Twitter Profile
Shalini Subramaniam

@shalsubra

Medical Oncologist @SWSLHD | PhD Student @Sydney_Uni | Research Fellow @TrialsCentre | Interests: lung/GU/breast cancer; improving doctor-patient communication

ID: 121351107

calendar_today09-03-2010 06:48:16

91 Tweet

223 Followers

282 Following

Dr Deme Karikios (@dkarikios) 's Twitter Profile Photo

Lovely work from Shalini Subramaniam Patients' perception of the benefits of palliative systemic therapy for advanced cancer - Subramaniam - 2024 - Internal Medicine Journal - Wiley Online Library onlinelibrary.wiley.com/doi/10.1111/im… Belinda Kiely martinst

Dr Andrew Parsonson (@aoparsonson) 's Twitter Profile Photo

A team effort with Anuradha Vasista @brownjlauren Belinda Kiely et al 📝 🙌 simple multiples of the median OS from RCTs can be used to estimate and communicate #prognosis for patients with advanced breast cancer starting endocrine therapy doi.org/10.1111/ajco.1… 🧵 1/X

Sam Stevens (@samuelxstevens) 's Twitter Profile Photo

Calling Australian Oncologists at MOGA and beyond! Contribute your perspectives on the time toxicity of palliative systemic treatments by taking our 10 minute survey - more in the poster hall at #MOGA24 Medical Oncology Group of Australia Follow the link to participate: redcap.slhd.nsw.gov.au/surveys/?s=EFD…

Calling Australian Oncologists at MOGA and beyond! Contribute your perspectives on the time toxicity of palliative systemic treatments by taking our 10 minute survey - more in the poster hall at #MOGA24 <a href="/MOGA_ORG/">Medical Oncology Group of Australia</a>  
Follow the link to participate: redcap.slhd.nsw.gov.au/surveys/?s=EFD…
Shalini Subramaniam (@shalsubra) 's Twitter Profile Photo

Come work with the Medical Oncology Clinical Trials Unit at Bankstown-Lidcombe Hospital! We are an expanding trials unit serving a diverse multicultural community. Applications close 08/09/2024. iworkfor.nsw.gov.au/job/clinical-t…

Shalini Subramaniam (@shalsubra) 's Twitter Profile Photo

Is metastatic cancer curable? Seeking perspectives of oncologists and trainees who treat solid tumours. 🔗: tinyurl.com/vfcwjmac ⏱️: <15mins ✅: med/clin oncs from 🌎🌍🌏 Medical Oncology Group of Australia ausyoungoncs ANZUP Thoracic Oncology Group of Australasia OncoAlert #OncTwitter

Is metastatic cancer curable? Seeking perspectives of oncologists and trainees who treat solid tumours. 

🔗: tinyurl.com/vfcwjmac
⏱️: &lt;15mins
✅: med/clin oncs from 🌎🌍🌏

<a href="/MOGA_ORG/">Medical Oncology Group of Australia</a> <a href="/ausyoungoncs/">ausyoungoncs</a> <a href="/ANZUPtrials/">ANZUP</a> <a href="/TOGAANZ/">Thoracic Oncology Group of Australasia</a> <a href="/OncoAlert/">OncoAlert</a> #OncTwitter
Sam Stevens (@samuelxstevens) 's Twitter Profile Photo

Thanking 88 participants who have completed our survey! 🙏🙏🙏 ❓Time Toxicity of systemic rx 🧑‍⚕️Aus Med Oncs + Trainees ⏲️5-10 min - not time toxic! 🔗redcap.slhd.nsw.gov.au/surveys/?s=EFD… Pls help us out + share 📢📢📢 Pls also consider important research by: Jenn Soon Is less more?

Thanking 88 participants who have completed our survey! 🙏🙏🙏 
❓Time Toxicity of systemic rx
🧑‍⚕️Aus Med Oncs + Trainees
⏲️5-10 min - not time toxic! 
🔗redcap.slhd.nsw.gov.au/surveys/?s=EFD…

Pls help us out + share 📢📢📢

Pls also consider important research by:
<a href="/drjnnsoon/">Jenn Soon</a> Is less more?
Yu Yang Soon (@yysoon01) 's Twitter Profile Photo

Why do the TheraP and VISION trials show different effects of Lu-177 PSMA on survival in advanced prostate cancer? It may be due to different comparison treatments. jamanetwork.com/journals/jaman… Martin Stockler Ian Marschner Michael Hofman Ian Davis (Bluesky @profiand) Louise Emmett

The Lancet Oncology (@thelancetoncol) 's Twitter Profile Photo

Being presented at ASCO #GU25 ⬇️ Overall survival & QOL results from ENZA-p: [177Lu]Lu-PSMA-617 plus enzalutamide vs enzalutamide in metastatic castration-resistant #prostatecancer Louise Emmett Ian Davis Michael Hofman Martin Stockler ANZUP bit.ly/3ExZgPI

Michael Hofman (@drmhofman) 's Twitter Profile Photo

PSMA PET/CT or radioligand therapy mentioned 600 times in the ASCO #GU25 prostate cancer abstracts (advanced and localized). I think around 1 in 5 of abstracts contain PSMA !! Amazing to see the uptake of this new technology over the last 10 years. ENZA-P was my highlight from

PSMA PET/CT or radioligand therapy mentioned 600 times in the <a href="/ASCO/">ASCO</a> #GU25 prostate cancer abstracts (advanced and localized). I think around 1 in 5 of abstracts contain PSMA !! Amazing to see the uptake of this new technology over the last 10 years. 

ENZA-P was my highlight from
OncoAlert (@oncoalert) 's Twitter Profile Photo

ENZA-P Just published at Lancet Oncology & Presented at #GU25 Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant #ProstateCancer buff.ly/41iv5oq In the ENZA-p trial, the addition

ENZA-P Just published at Lancet Oncology &amp; Presented at #GU25
Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant #ProstateCancer 

buff.ly/41iv5oq 

In the ENZA-p trial, the addition
Louise Emmett (@drlouiseemmett) 's Twitter Profile Photo

PSMA-PET total tumour volume is prognostic for overall survival in mCRPC. thelancet.com/journals/lanon… PSMA-PET value extends beyond selection for PSMA-RLT therapy in metastatic prostate cancer. urotoday.com/video-lectures… ANZUP @trialscentre Prostate Cancer Foundation Movember Australia

PSMA-PET total tumour volume is prognostic for overall survival in mCRPC.
thelancet.com/journals/lanon…

PSMA-PET value extends beyond selection for PSMA-RLT therapy in metastatic prostate cancer.
urotoday.com/video-lectures…

<a href="/ANZUPtrials/">ANZUP</a> @trialscentre <a href="/PCFnews/">Prostate Cancer Foundation</a> <a href="/MovemberAUS/">Movember Australia</a>
Ian Davis (@prof_iand) 's Twitter Profile Photo

Third LancetOncology paper to come out of the ANZUP #ENZAp #ProstateCancer #pcsm #ClinicalTrial - congratulations Louise Emmett and grateful thanks to all investigators, research teams, and of course the participants who have helped move the whole field ahead.

Advanced Prostate Cancer Consensus Conference (@apccc_lugano) 's Twitter Profile Photo

Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901) thelancet.com/journals/lanon… This prespecified substudy of the ENZA-p phase 2 trial evaluated whether baseline quantitative

Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901)

thelancet.com/journals/lanon…

This prespecified substudy of the ENZA-p phase 2 trial evaluated whether baseline quantitative